Exhibit 99.1

Quintiles Reports Fourth Quarter 2013 Results

• $1.0 billion of service revenues in the fourth quarter; First billion dollar service revenue quarter in Quintiles’ history
• Net new business wins of $1.3 billion representing a book-to-bill ratio of 1.29
• Fourth quarter diluted adjusted EPS increased 41% to $0.58 and adjusted net income increased 58% to $76.5 million compared to the fourth quarter of 2012
• Fourth quarter GAAP reported diluted EPS increased 83% to $0.55 and GAAP reported net income increased 109% to $73.0 million compared to the fourth quarter of 2012
• Full year 2014 diluted adjusted EPS guidance of $2.33 - $2.46 per share representing growth of 11% to 17%

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--February 13, 2014--Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the fourth quarter ended December 31, 2013.

For the three months ended December 31, 2013, the Company’s growth in service revenues, excluding the impact of foreign currency fluctuations (“constant currency service revenue growth”), increased 7.7%, or $72.5 million compared to the same period last year. At actual foreign exchange rates, service revenues grew $58.1 million to $1.0 billion, representing growth of 6.2% compared to the same period last year including an unfavorable foreign currency impact of 1.5%, or $14.4 million. Constant currency service revenue growth resulted from growth in the Product Development segment including the acquisition of Novella Clinical completed in September 2013, partially offset by a decrease in the Integrated Healthcare Services segment.

Adjusted income from operations was $129.2 million in the fourth quarter of 2013, representing growth of 12.8% compared to the prior year. The adjusted income from operations margin was 12.9%, representing 80 basis points of expansion compared to the same period last year. Adjusted net income was $76.5 million in the fourth quarter of 2013, representing growth of 58.2% compared to the same period last year. Diluted adjusted earnings per share was $0.58 in the fourth quarter ended December 31, 2013, representing growth of 41.5% compared to the same period last year. Reported GAAP income from operations was $127.0 million, reported GAAP net income was $73.0 million and reported GAAP diluted earnings per share was $0.55 for the three months ended December 31, 2013. Reconciliations of the non-GAAP measures, including adjusted income from operations, adjusted net income and diluted adjusted earnings per share to the corresponding GAAP measures are attached to this press release.

For the year ended December 31, 2013, the Company’s constant currency service revenue growth was 5.1% or $186.6 million compared to 2012. At actual foreign exchange rates, the Company’s service revenues grew 3.1% compared to 2012 to $3.8 billion, including an unfavorable foreign currency impact of 2.0% or $70.6 million. Adjusted income from operations for the year ended December 31, 2013 was $504.1 million, representing growth of 13.2% and 110 basis points of margin expansion compared to the same period last year. Adjusted net income was $268.9 million for the year ended December 31, 2013, representing growth of 28.7% compared to the same period last year. Diluted adjusted earnings per share was $2.10 for the year ended December 31, 2013, representing growth of 18.6% compared to the same period last year. Reported GAAP income from operations was $462.3 million, reported GAAP net income was $226.6 million and reported GAAP diluted earnings per share was $1.77 for the year ended December 31, 2013.

Net new business of $1.3 billion and $4.9 billion was recorded for the quarter and twelve months ended December 31, 2013, respectively, representing a book-to-bill ratio of 1.29 for both the fourth quarter and year ended December 31, 2013. This net new business contributed to an ending backlog of $9.9 billion on December 31, 2013.

“We enter 2014 positioned for growth with our strong 2013 performance,” said Tom Pike, chief executive officer. “2013 was a year of entry into the public markets punctuated by the strength of our leadership, customer relationships, deepening scientific and therapeutic expertise, and enhanced data and analytics capabilities, all coupled with predictable service delivery. We made progress on our growth strategy, concluding 2013 with another strong quarter in net new business generating a book-to-bill ratio of 1.29 for the full year. In addition, we expanded our best in industry income from operations margins and grew our full year diluted adjusted earnings per share by 18.6%, compared to the prior year. All of these achievements are enabled by the talented and dedicated team of professionals working at Quintiles.

“We continue to see strong demand across all clinical phases of the pipeline with a greater interest in end-to-end integrated solutions underpinned with data analytics. We are well positioned entering 2014 with the largest backlog in the industry at $9.9 billion dollars which will fuel 2014 constant currency service revenue and earnings growth. We have one foot in today focused on delivery and another foot in tomorrow focused on redefining our industry with innovations and valued solutions that we believe will contribute to improving the healthcare landscape.”

The Product Development segment net new business totaled $964.0 million in the current quarter and $3.8 billion for the twelve months ended December 31, 2013 which translates into a book-to-bill ratio of 1.24 for the fourth quarter and 1.29 for the year ended December 31, 2013. Product Development’s constant currency service revenue growth was 10.7%, or $75.1 million during the fourth quarter of 2013 compared to the same period last year. At actual foreign exchange rates, Product Development’s service revenues grew 10.2% compared to the same period last year to $775.0 million. The constant currency service revenue growth resulted from a volume-related increase in core clinical services and global labs and the acquisition of Novella in 2013, partially offset by the continuing wind down of two large projects. Product Development’s income from operations margin was 19.7% for the fourth quarter, representing an improvement of 190 basis points compared to the same period last year.

The Integrated Healthcare Services segment net new business totaled $335.0 million in the current quarter and $1.1 billion for the year ended December 31, 2013 which translates into a book-to-bill ratio of 1.47 for the fourth quarter and 1.27 for the year ended December 31, 2013. On a constant currency basis, Integrated Healthcare Services’ service revenues declined 1.1% or $2.6 million during the fourth quarter of 2013 compared to the same period last year primarily due to lower new business won in the first half of 2013, negative scope modifications and cancellations. At actual foreign exchange rates, Integrated Healthcare Services’ service revenues declined 5.7%, or $13.9 million, compared to the same period last year to $228.9 million of which $11.3 million or 4.6% was due to unfavorable foreign currency fluctuations. Integrated Healthcare Services’ income from operations margin was 5.1% for the fourth quarter.

General corporate and unallocated expenses were $35.4 million during the fourth quarter compared to $37.5 million for the same period last year and $128.0 million for the full year ended December 31, 2013 compared to $123.3 million for the same period in 2012.

Interest expense was $26.8 million during the fourth quarter compared to $38.4 million for the same period last year and $123.5 million for the full year ended December 31, 2013 compared to $134.4 million for the same period in 2012.

The GAAP effective income tax rate was 27.5% for the fourth quarter of 2013 compared to 36.3% for the same period in 2012 and 29.7% for the full year ended December 31, 2013 compared to 34.9% for 2012. The effective income tax rates for the three and twelve months ended December 31, 2013 were positively impacted by the Company’s change in income tax accounting as a result of its change in assertion that the undistributed earnings of most of the Company’s foreign subsidiaries are indefinitely reinvested outside of the United States.

Recent Events

The Company repurchased approximately 153,200 shares of its common stock and 2.0 million vested in-the-money employee stock options under the equity repurchase program approved in October 2013 for an aggregate purchase price of $65.5 million. As of December 31, 2013, $59.5 million of authorization remains available under the repurchase program.

Financial Guidance

For 2014, the Company expects to achieve service revenues between $4.09 billion and $4.15 billion, representing a constant currency growth range of 7.4% to 9.0%, and diluted adjusted earnings per share of $2.33 to $2.46 per share, representing growth of 11.0% to 17.1% with diluted GAAP earnings per share between $2.26 and $2.40 per share, and an annual effective income tax rate estimated at approximately 30%. This financial guidance assumes the first of January foreign currency exchange rates, but does not reflect the potential impact of future equity repurchases.

Webcast & Conference Call Details

Quintiles will host a conference call at 8:00 a.m. EST today to discuss its fourth quarter 2013 financial results. To participate, please dial +1 (855) 484-7367 or +1 (631) 259-7541 outside the United States approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible, live via webcast, on the Investors section of the Quintiles website at www.quintiles.com/investors. An archived replay of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EST today.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of approximately 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company’s expectations due to a number of factors, including that most of the Company’s contracts may be terminated on short notice, and that the Company may be unable to maintain large customer contracts or to enter into new contracts; the Company may under price contracts or overrun its cost estimates; the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship; the market for the Company’s services may not grow as the Company expects; the Company may be unable to maintain information systems or effectively update them; customer or therapeutic concentration could harm the Company’s business; the Company’s business is subject to risks associated with international operations, including economic, political and other risks such as compliance with a myriad of foreign laws and regulations, complications from conducting clinical trials in multiple countries simultaneously and changes in exchange rates; the Company may be unable to successfully develop and market new services or enter new markets; government regulators or customers may limit the scope of prescription or withdraw products from the market, and government regulators may impose new regulations affecting the Company’s business; the Company’s failure to perform services in accordance with contractual requirements, regulatory standards and ethical considerations may subject it to significant costs or liability, damage its reputation and cause it to lose existing business or not receive new business; the Company’s services are related to treatment of human patients, and it could face liability if a patient is harmed; exchange rate fluctuations may affect the Company’s results of operations and financial condition; the Company’s effective income tax rate may fluctuate, which may adversely affect our operations, earnings and earnings per share; the Company may be unable to successfully identify, acquire and integrate existing businesses, services and technologies; and the Company has substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect the Company’s financial condition. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” section in the final prospectus dated May 8, 2013 filed with the Securities and Exchange Commission relating to the Company’s initial public offering and the Company’s other filings with the Securities and Exchange Commission. Unless legally required, the Company undertakes no obligation to update any forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Use of Non-GAAP Financial Measures

This press release includes adjusted EBITDA, adjusted income from operations, adjusted income from operations margin, adjusted net income and diluted adjusted earnings per share, each of which is a financial measure not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Management believes that these non-GAAP measures provide useful supplemental information to management and investors regarding the underlying performance of the Company’s business operations and are more indicative of core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business. These non-GAAP measures are performance measures only and are not measures of the Company’s cash flows or liquidity, nor are they alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Investors and potential investors are encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP measures attached to this press release.

Internet Posting of Information: The Company routinely posts information that may be important to investors in the 'Investors' section of the Company’s website at www.Quintiles.com. The Company encourages investors and potential investors to consult the Company’s website regularly for important information about the Company.

Click here to subscribe to Mobile Alerts for Quintiles.

QUINTILES TRANSNATIONAL HOLDINGS INC. AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Continued)

(unaudited)

(1) Incremental expense incurred for repricings of share-based awards. The amount represents only the incremental amount of share-based compensation expense incurred in the quarter that the repricing occurred.

(2) Management fees were previously paid to affiliates of certain of the Company’s shareholders pursuant to a management agreement. The year ended December 31, 2013 includes a $25.0 million fee paid in connection with the termination of the management agreement.

(3) The tax effect of adjustments was based on the respective transactions income tax rate, which was 38.5%, with the exception of restructuring costs which were tax effected at 28.2% for the full-year 2013 and 32.3% during the current quarter compared with 36.0% in the 2012 periods.

(4) Other income tax adjustments remove the impact of certain discrete adjustments on the Company’s income tax expense. The Company’s effective income tax rate in the 2013 periods was impacted by the Company’s change in assertion regarding the undistributed earnings of most of the Company’s foreign subsidiaries, which are now considered to be indefinitely reinvested outside of the United States. As a result of the assertion change, in the second quarter of 2013, we recorded an $8.1 million discrete income tax benefit to reverse the deferred income tax liability previously recorded on undistributed foreign earnings. In addition, in the second quarter of 2013, the Company settled certain intercompany notes that had previously been considered long term investments, which resulted in an $11.2 million discrete income tax expense.

Restructuring costs are tax effected at approximately 30.0%.

CONTACT:
Quintiles Transnational Holdings Inc.
Phil Bridges, Media Relations, 919-998-1653 (office) or 919-457-6347 (mobile)
phil.bridges@quintiles.com
or
Karl Deonanan, Investor Relations, 919-998-2789
InvestorRelations@quintiles.com